MetaCap

Charles River Laboratories International Inc. (CRL)

NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

314.32-13.61 (-4.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$15.06B
P/E (TTM)
341.65
52-week range
146.20 – 379.63
Day range
310.52 – 327.23
Volume / Avg
1.15M / 1.04M
Beta
—

52-week range

$146.20$379.63

CRL stock today

Charles River Laboratories International (CRL) closed at $314.32 on Nov 20, down 4.15% (-$13.61), versus the S&P 500's 3.70% decline. Shares are 17.2% below their 52-week high of $379.63, set on Oct 29, 2026 and 115.0% above the 52-week low of $146.20, in the middle of the past year's range. CRL is up 57.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 87.5%.

At 341.7x trailing earnings, Charles River Laboratories International trades above the peer-group median of 66.6x. Its forward P/E of 24.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Charles River Laboratories International

Company profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Ms. Birgit Girshick
Headquarters
Wilmington, MA
Employees
18,300
IPO year
2000
Website
criver.com

Financial highlights

Full financials

In fiscal 2025, Charles River Laboratories International generated $4.02 billion in revenue, down 0.9% from fiscal 2024, its first annual decline since 2024. Charles River Laboratories International reported a net loss of $144.3 million, compared with net income of $22.2 million a year earlier. Operating margin was 0.6%.

Charles River Laboratories International annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.02B$4.05B$4.13B$3.98B$3.54B
Growth-0.85%-1.92%+3.86%+12.31%+21.08%
Net income$-144.34M$22.20M$474.62M$486.23M$390.98M
EPS (diluted)$-2.91$0.20$9.22$9.48$7.60

Analyst forecast

Forecast

Consensus (17 analysts)

buy

Avg. price target

$350.57+11.53%

  • Strong buy 3
  • Buy 11
  • Hold 2
  • Sell 1
  • Strong sell 0

Target range

Low $145.00High $400.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$6.86 vs $2.98
Surprise
+130.20%

CRL news

All CRL news

Charles River Laboratories International peers

Health Care sector
CRL peer companies
CompanyPrice% ChgMarket capCompare
ICLRICON plc186.71-1.92%$13.99Bvs CRL
MEDPMedpace Holdings Inc.610.54-3.70%$17.08Bvs CRL
INCYIncyte Corp.114.63-1.07%$23.36Bvs CRL
ABSIAbsci Corporation7.51-7.97%$1.30Bvs CRL
OABIOmniAb Inc.4.66-7.36%$679.71Mvs CRL
NRCNRC Health25.16+0.68%$533.93Mvs CRL
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs CRL
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs CRL

Indexes, lists and sector

Charles River Laboratories International stock FAQ

What is Charles River Laboratories International's stock price today?

CRL last traded at $314.32 as of Nov 20, 4:00 PM EST, down 4.15% on the day. Prices are delayed at least 15 minutes.

What is CRL's P/E ratio?

CRL trades at a trailing P/E ratio of 341.65 and a forward P/E of 24.24, compared with a median of 66.6 for its closest peers.

Is Charles River Laboratories International in the S&P 500?

Yes. Charles River Laboratories International (CRL) is a constituent of the S&P 500 index.

Who is Charles River Laboratories International's CEO?

Ms. Birgit Girshick is the chief executive officer of Charles River Laboratories International Inc., which has about 18,300 employees.

What is the CRL 52-week high?

The 52-week high for CRL is $379.63 and the 52-week low is $146.20. The stock is currently 17.2% below its high.

Compare CRL